Isolated groin infection following crossover femoral bypass is not uncommon, and its management may be challenging, especially in medically high-risk patients. When an in situ replacement is appropriate, using an autologous vein (femoral or saphenous) would be the preferred method; however, this may not always be feasible. The authors used cryopreserved femoral vein grafts for in situ replacement of femorofemoral bypass grafts with excellent results in 3 high-risk patients who developed early graft infections and failed graft preservation attempts. In situ replacement of infected femorofemoral grafts using a cryopreserved femoral vein graft can be considered as a second-line intervention when an adequately sized autologous vein is unavailable or unusable or is not feasible in high-risk patients.
Liekweg WG, Greenfield LJVascular prosthetic infections: collected experience and results of treatment . Surgery. 1977;81:335-342.
3.
Hakaim A., Hertzer N., O'Hara P, Krajewski L, Beven E. Autogenous vein grafts for femorofemoral revascularization in contaminated or infected fields. J Vasc Surg.1994;19:912-915.
4.
Jicha D., Reilly L., Kuestner L., Stoney R.Durability of cross-femoral grafts after aortic graft infection: the fate of autogenous conduits. J Vasc Surg. 1995;22:393-407.
5.
Meneghetti A. , MacDonald P., Reid J., Sladen J., Turnbull R.Patency of superficial femoral vein employed as a crossover femoral artery bypass conduit. Ann Vasc Surg . 2002;16:746-750.
6.
D'Addio V., Ali A., Timaran C., et al. Femorofemoral bypass with femoral popliteal vein. J Vasc Surg.2005;42:35-39.
7.
Castier Y., Francis F., Cerceau P., et al. Cryopreserved arterial allograft reconstruction for peripheral graft infection. J Vasc Surg. 2005;41:30-37.
8.
Desgranges P. , Beaujan F., Brunet S., et al. Cryopreserved arterial allografts used for the treatment of infected vascular grafts. Ann Vasc Surg. 1998;12:583-588.
9.
Matsuura JH, Johansen KH, Rosenthal D., Clark MD, Clarke KA, Kirby LBCryopreserved femoral vein grafts for difficult hemodialysis access . Ann Vasc Surg. 2000; 14:50-55.
10.
Chiesa R., Astore D., Piccolo G., et al. Fresh and cryopreserved arterial homografts in the treatment of prosthetic graft infections: experience of the Italian Collaborative Vascular Homograft Group. Ann Vasc Surg. 1998;12:457-462.
11.
Bandyk DF, Novotney ML, Back MR, Johnson BL, Schmacht DCExpanded application of in situ replacement for prosthetic graft infection . J Vasc Surg. 2001;34: 411-419.
Dosluoglu HH , Schimpf DK, Schultz R., Cherr GSPreservation of infected and exposed vascular grafts using vacuum assisted closure (VAC) without muscle flap coverage. J Vasc Surg. 2005;42: 989-992.
14.
Calligaro KD , Veith FJ, Schwartz ML, et al. Selective preservation of infected prosthetic arterial grafts: analysis of a 20-year experience with 120 extracavitary-infected grafts. Ann Surg.1994;220:461-471.
15.
Persson AV, Dyer VE, West LSFemoral-to-femoral bypass graft. Surg Clin North Am. 1980;60:537-544.
16.
Kuang AA, Renz JF, Ferrell LD, et al. Failure patterns of cryopreserved vein grafts in liver transplantation . Transplantation. 1996;62:742-747.
17.
Lehalle B., Geschier C., Fieve G., Stoltz JFEarly rupture and degeneration of cryopreserved arterial allografts . J Vasc Surg. 1997;25:751-752.
18.
Farber A., Major K., Wagner WH, et al. Cryopreserved saphenous vein allografts in infrainguinal revascularization: analysis of 240 grafts. J Vasc Surg. 2003;38: 15-21.
19.
Verhelst R. , Lacroix V., Vraux H., et al. Use of cryopreserved arterial homografts for management of infected prosthetic grafts: a multicentric study. Ann Vasc Surg. 2000;14:602-607.
20.
Fujitani RM , Bassiouny HS, Gewertz BL, Glagov S., Zarins CKCryopreserved saphenous vein allogenic homografts: an alternative conduit in lower extremity arterial reconstruction in infected fields. J Vasc Surg. 1992;15:519-526.
